Robert Arch, OncoSec Medical CEO

On­coSec re­ports flop for IL-12/Keytru­da com­bo in what may be fi­nal blow

A six-year tri­al test­ing the com­bi­na­tion of On­coSec Med­ical’s IL-12 ther­a­py with Mer­ck’s Keytru­da has end­ed in fail­ure.

The com­bo

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.